Responses
Regular and young investigator award abstracts
Clinical trials in progress
356 Baseline PD-L1 expression and tumor immune infiltration is associated with clinical response in patients with r/r DLBCL treated with DPX-Survivac, low-dose cyclophosphamide and pembrolizumab
Compose a Response to This Article
Other responses
No responses have been published for this article.
